DexCom (NASDAQ:DXCM) Reports Quarterly Earnings
DexCom (NASDAQ:DXCM – Get Rating) released its quarterly earnings data on Thursday. The medical device company reported earnings per share of $0.32 for the quarter, missing analyst consensus estimates of $0.52 per ($0.20), MarketWatch Earnings reports. DexCom had a net margin of 6.32% and a return on equity of 12.87%. The company posted revenue of $628.80 million in the quarter, compared to analyst estimates of $623.97 million. During the same period of the previous year, the company achieved EPS of $0.33. The company’s quarterly revenue increased 24.5% year over year.
Shares of NASDAQ DXCM traded at $4.65 during Friday trading, hitting $408.58. The company had a trading volume of 1,357,518 shares, compared to an average volume of 833,490. DexCom has a 52-week low of $318.45 and a 52-week high of $659.45. The company’s 50-day moving average is $455.02 and its 200-day moving average is $501.82. The company has a market capitalization of $40.09 billion, a P/E ratio of 268.18, a PEG ratio of 7.95 and a beta of 0.94. The company has a debt ratio of 0.76, a quick ratio of 4.62 and a current ratio of 5.11.
DexCom shares will be split on Friday, June 10. The 4-1 split was announced on Friday, March 25. The newly issued shares will be payable to shareholders after market close on Thursday, June 9.
A number of research companies have recently commented on DXCM. Piper Sandler lowered her price target on DexCom shares from $725.00 to $480.00 in a research note on Friday. Citigroup reduced its price target on DexCom from $660.00 to $630.00 in a Friday, February 11 research note. BTIG Research raised its target price on DexCom shares from $535.00 to $560.00 in a Monday, April 18 research report. StockNews.com launched coverage on DexCom shares in a research report on Thursday, March 31. They have set a “holding” rating on the stock. Finally, Robert W. Baird lowered his price target on DexCom shares from $625.00 to $560.00 in a Friday, February 11 research report. One research analyst has rated the stock with a sell rating, two have issued a hold rating and sixteen have assigned the company a buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $544.50.
Separately, director Barbara Kahn sold 4,666 shares of the company in a transaction on Thursday, February 10. The stock was sold at an average price of $442.35, for a total value of $2,064,005.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, CEO Kevin R. Sayer sold 3,000 shares of the company in a transaction on Monday, February 14. The shares were sold at an average price of $418.04, for a total value of $1,254,120.00. The disclosure of this sale can be found here. In the past ninety days, insiders have sold 10,898 shares of the company valued at $4,835,482. 0.52% of the shares are currently held by insiders of the company.
Several large investors have recently changed their stake in the company. Chicago Partners Investment Group LLC increased its holdings of DexCom stock by 3.5% during the fourth quarter. Chicago Partners Investment Group LLC now owns 730 shares of the medical device company valued at $297,000 after acquiring 25 additional shares last quarter. Toroso Investments LLC increased its stake in DexCom by 4.7% in the fourth quarter. Toroso Investments LLC now owns 2,575 shares of the medical device company valued at $1,383,000 after buying 115 additional shares last quarter. Horizon Investments LLC increased its position in DexCom by 8.1% in the fourth quarter. Horizon Investments LLC now owns 2,949 shares of the medical device company worth $1,583,000 after buying 222 additional shares in the last quarter. Flagship Harbor Advisors LLC purchased a new equity stake in DexCom during Q4 worth approximately $200,000. Finally, EP Wealth Advisors LLC increased its stake in DexCom shares by 63.6% during the 4th quarter. EP Wealth Advisors LLC now owns 1,134 shares of the medical device company valued at $609,000 after buying 441 additional shares in the last quarter. 95.14% of the shares are held by institutional investors.
DexCom Company Profile (Get an assessment)
DexCom, Inc, a medical device company, is focused on the design, development and marketing of Continuous Glucose Monitoring (CGM) systems in the United States and around the world. The company provides its systems to people with diabetes, as well as healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; The Dexcom Real-Time API, which allows guest third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, which is designed to replace fingertip blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in DexCom right now?
Before you consider DexCom, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and DexCom wasn’t on the list.
Although DexCom currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here